Biologics and Public Heath: Prospects and Challenges

Owoeye, O and Owoeye, O 2018, 'Biologics and Public Heath: Prospects and Challenges', Journal of Law and Medicine, vol. 26, no. 1, pp. 170-187.

Document type: Journal Article
Collection: Journal Articles

Title Biologics and Public Heath: Prospects and Challenges
Author(s) Owoeye, O
Owoeye, O
Year 2018
Journal name Journal of Law and Medicine
Volume number 26
Issue number 1
Start page 170
End page 187
Total pages 18
Publisher Thomson Reuters
Abstract Biotechnology has been used by humankind for thousands of years and it remains a very important part of human medicine. Biotechnology is particularly relevant to the creation of new medicines and vaccines. Biotechnology drugs or biologics are becoming increasingly popular in the life sciences sector. Biologics were estimated to account for US$289 billion pharmaceutical sales in 2014 and are projected to reach US$445 billion in 2019. It is also anticipated that biologics' share of global prescription and over-the-counter pharmaceutical sales will rise to 26% by 2019. Biological medicines are capable of being developed to cure life-threatening diseases that used to be completely incurable. While biologics have unprecedented therapeutic effects, though, they also raise significant quality and patient safety issues. This article discusses some of the regulatory challenges relating to biologics. It also explores mechanisms that may be adopted to promote the development of new biologics and access to biological drugs especially in low income countries.
Subject Intellectual Property Law
Keyword(s) biologics
public health
regulating biologics
Copyright notice © 2018 Thomson Reuters (Professional) Australia Limited
ISSN 1320-159X
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in Thomson Reuters Web of Science Article
Access Statistics: 28 Abstract Views  -  Detailed Statistics
Created: Thu, 21 Feb 2019, 12:10:00 EST by Catalyst Administrator
© 2014 RMIT Research Repository • Powered by Fez SoftwareContact us